Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Irinotecan with FOLFOX and Bevacizumab for Colorectal Peritoneal Metastases
NCT06003998Phase 2Unknown
- Sponsor
- Catharina Ziekenhuis
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Catharina Ziekenhuis. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06003998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003998.